A hormone treatment called tesamorelin doesn't change the fat under the skin in people with HIV who have excess belly fat after six months of treatment.

Scientific Claim

Tesamorelin does not significantly affect subcutaneous adipose tissue area in HIV-infected adults with abdominal fat accumulation over 6 months.

Original Statement

“SAT (cm2) ... treatment effect −6cm2 [95% CI −19, 7], P = 0.29”

From study:Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The null result is appropriately described using 'does not significantly affect' as the study design supports descriptive statements about lack of effect.

Evidence from Studies

Supporting (1)

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Randomized Controlled Trial

Human

2014 Jul 23-30

Contradicting (0)

No contradicting evidence found

Source Study

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Score: 73

DOI: 10.1001/jama.2014.8334

Similar Assertions

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

93%

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

93%

Tesamorelin reduced belly fat without affecting other fat or weight in HIV patients with abdominal obesity.

93%

Tesamorelin only targets dangerous belly fat in HIV patients, leaving other fat stores like arms and legs unchanged.

93%

In a randomized, double-blind, placebo-controlled trial of 404 HIV-infected patients with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue by 10.9% (21 cm²) after 6 months compared to less than 1% in the placebo group, with concurrent reductions in waist circumference and trunk fat and increases in IGF-I levels.

92%